Signature Wealth Management Partners LLC Has $763,000 Stake in Eli Lilly and Company $LLY

Signature Wealth Management Partners LLC lifted its position in shares of Eli Lilly and Company (NYSE:LLY) by 25.2% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 978 shares of the company’s stock after acquiring an additional 197 shares during the quarter. Signature Wealth Management Partners LLC’s holdings in Eli Lilly and Company were worth $763,000 at the end of the most recent reporting period.

Several other hedge funds also recently modified their holdings of LLY. Brighton Jones LLC boosted its holdings in shares of Eli Lilly and Company by 22.0% during the 4th quarter. Brighton Jones LLC now owns 9,597 shares of the company’s stock valued at $7,409,000 after acquiring an additional 1,730 shares in the last quarter. Revolve Wealth Partners LLC boosted its holdings in shares of Eli Lilly and Company by 2.8% during the 4th quarter. Revolve Wealth Partners LLC now owns 1,471 shares of the company’s stock valued at $1,136,000 after acquiring an additional 40 shares in the last quarter. Matrix Trust Co boosted its holdings in shares of Eli Lilly and Company by 25.9% during the 1st quarter. Matrix Trust Co now owns 267 shares of the company’s stock valued at $221,000 after acquiring an additional 55 shares in the last quarter. Beacon Financial Group boosted its holdings in shares of Eli Lilly and Company by 4.2% during the 1st quarter. Beacon Financial Group now owns 446 shares of the company’s stock valued at $368,000 after acquiring an additional 18 shares in the last quarter. Finally, Charles Schwab Trust Co boosted its holdings in shares of Eli Lilly and Company by 41.1% during the 1st quarter. Charles Schwab Trust Co now owns 453 shares of the company’s stock valued at $374,000 after acquiring an additional 132 shares in the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

Insider Transactions at Eli Lilly and Company

In other Eli Lilly and Company news, EVP Daniel Skovronsky acquired 1,000 shares of the stock in a transaction dated Tuesday, August 12th. The stock was purchased at an average cost of $634.40 per share, with a total value of $634,400.00. Following the transaction, the executive vice president owned 137,660 shares in the company, valued at approximately $87,331,504. The trade was a 0.73% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Jamere Jackson acquired 200 shares of the stock in a transaction dated Friday, August 8th. The stock was acquired at an average cost of $639.56 per share, with a total value of $127,912.00. Following the completion of the transaction, the director owned 9,402 shares in the company, valued at approximately $6,013,143.12. This represents a 2.17% increase in their position. The disclosure for this purchase can be found here. In the last 90 days, insiders purchased 4,514 shares of company stock worth $2,894,841. Corporate insiders own 0.13% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts recently weighed in on LLY shares. Daiwa America downgraded Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a report on Sunday, August 17th. Deutsche Bank Aktiengesellschaft lowered their target price on Eli Lilly and Company from $1,010.00 to $900.00 and set a “buy” rating for the company in a research report on Monday, August 11th. Leerink Partnrs lowered Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a research report on Thursday, August 7th. Daiwa Capital Markets lowered Eli Lilly and Company from an “outperform” rating to a “neutral” rating and set a $700.00 target price for the company. in a research report on Sunday, August 17th. Finally, Morgan Stanley lowered their target price on Eli Lilly and Company from $1,028.00 to $1,023.00 and set an “overweight” rating for the company in a research report on Friday. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating and ten have assigned a Hold rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $933.39.

Eli Lilly and Company Stock Performance

LLY stock opened at $840.46 on Friday. The stock has a 50-day moving average price of $734.60 and a 200-day moving average price of $766.47. Eli Lilly and Company has a 1-year low of $623.78 and a 1-year high of $937.00. The company has a current ratio of 1.28, a quick ratio of 1.00 and a debt-to-equity ratio of 1.86. The firm has a market cap of $795.47 billion, a PE ratio of 54.93, a price-to-earnings-growth ratio of 1.14 and a beta of 0.47.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings data on Thursday, August 7th. The company reported $6.31 earnings per share for the quarter, topping the consensus estimate of $5.59 by $0.72. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The firm had revenue of $15.56 billion during the quarter, compared to analyst estimates of $14.40 billion. During the same period last year, the company posted $3.92 EPS. The business’s quarterly revenue was up 37.6% on a year-over-year basis. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. As a group, equities research analysts expect that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.